Skip to content

Comparing morhine and fentanyl on anti platelet effect of ticagrelor

Comparison of effect of Morphine and fEntanyl on the platelet inhibition of Ticagrelor in patients with acute coronary syndrome - COMET

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/04/013423
Enrollment
126
Registered
2018-04-23
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- ACUTE CORONARY SYNDROME Health Condition 2: I21- Acute myocardial infarction Health Condition 3: I25- Chronic ischemic heart disease Health Condition 4: I200- Unstable angina

Interventions

Intervention1: Morphine: 2 to 8 mg of morphine could be given once every 5 min till side effects happen or symptom subside or maximum of 4 times
Dosage will be reduced to half if age is more than 75 or weight is less than 50 Kg Control Intervention1: Fentanyl: 1miG/Kg of Fentanyl will be given with a maximum dosage limit of 50 microgram. D

Sponsors

SRI RAMACHANDRA MEDICAL COLLEGE AND RESEARCH INSTITUTION
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with acute coronary syndrome and age >18 years

Exclusion criteria

Exclusion criteria: Patients who will be in altered sensorium status due to any other pathology which prohibits them from answering questions Patients who are already on dual anti platelet agents Patients who have been thrombolysed or before reaching ER at SRMC Patients who will not provide consent Patients who would have been administered analgesics in out of hospital settings Patients who receive Gp2b/3a inhibitors in emergency or in ambulance

Design outcomes

Primary

MeasureTime frame
Platelet reactivity measured using light transmission aggregometry at SECOND hour between the two groupsTimepoint: SECOND HOUR

Secondary

MeasureTime frame
1.Comparison of pain scale amongst the groups. 2.Comparison of adverse events that include nausea, vomiting, bradycardia, hypotension.Timepoint: second hour

Countries

India

Contacts

Public ContactS NAGENDRA BOOPATHY

SRI RAMAMCHANDRA MEDICAL COLLEGE AND RESEARCH INSTITUTE, CHENNAI

drsnboopathy@gmail.com9789836339

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 24, 2026